Akouos to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

Akouos, a precision genetic medicine company focused on gene therapies for hearing loss, announced that CEO Manny Simons participated in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Healthcare Conference. This event will occur from November 29 to December 2, 2021. The chat will be available on Akouos's website starting November 22, 2021, for 14 days. Akouos aims to develop therapies to restore and improve hearing for individuals suffering from disabling hearing loss, utilizing proprietary AAV vectors and innovative delivery methods.

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 33^rd Annual Healthcare Conference taking place November 29 to December 2, 2021.

The fireside chat will be available for on-demand viewing through the investor section of Akouos’s website at www.akouos.com beginning today, Monday, November 22, 2021, and will be available for 14 days following the conference.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com

FAQ

What is Akouos's participation in the Piper Sandler Healthcare Conference?

Akouos's CEO Manny Simons participated in a pre-recorded fireside chat for the Piper Sandler 33rd Annual Healthcare Conference.

When will the Akouos fireside chat be available for viewing?

The fireside chat will be available on Akouos's website starting November 22, 2021, and can be viewed for 14 days.

What is the focus of Akouos's gene therapies?

Akouos focuses on developing gene therapies aimed at restoring and improving hearing for individuals with disabling hearing loss.

What type of technology does Akouos utilize in its therapies?

Akouos uses a proprietary adeno-associated viral (AAV) vector library and novel delivery methods to develop its gene therapies.

When is the Piper Sandler Healthcare Conference taking place?

The Piper Sandler 33rd Annual Healthcare Conference is scheduled from November 29 to December 2, 2021.